PCV18 COST-UTILITY ANALYSIS OF TWO KINDS OF THERAPY FOR ACUTE ISCHEMIC STROKE  by Fang, Z
A152 Abstracts
be utilized in clinical practice. The analytic framework in this comparative effective-
ness analysis demonstrated the Coaguchek XS device to have a signiﬁcantly higher 
level of agreement with the core lab compared to the Hemochron device. This analysis 
led our institution to select the Coaguchek XS for use in our anticoagulation clinics 
on the basis of a superior quality and safety proﬁle.
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OBJECTIVES: To compare blood pressure (BP) goal achievement associated with the 
use of valsartan-based single pill combination (SPC) vs. ARB-based free combination 
(FC) among adult hypertension patients in South Central region (TX, AL, MS, LA, 
KS, TN, MO, AR & OK). METHODS: Data were collected from physician-adminis-
tered chart review of adult hypertension patients. All patients had uncontrolled BP 
before initiating one of the index therapies (SPC: valsartan+amlodipine or 
valsartan+HCTZ, FC: ARB+CCB or ARB+HCTZ) between 07/2008 and 06/2009. Up 
to 3 BPs were collected starting from 45 days after the therapy initiation. BP goal was 
<130/80 mmHg for patients with diabetes, chronic renal disease or coronary heart 
disease; or <140/90 mmHg for patients without these comorbidities. Kaplan-Meier 
method with log-rank test was used to compare rates of BP goal achievement associ-
ated with SPC vs. FC over time. Cox proportional hazard models were used to estimate 
the likelihood of BP goal achievement associated with SPC vs. FC, controlling for 
demographics, baseline BP, hypertension history, comorbidities, prior and concurrent 
use of anti-hypertensive medications, and physician specialty. RESULTS: The chart 
review included 813 patients: 415 on SPC (210 valsartan+amlodipine and 205 
valsartan+HCTZ) and 398 on FC (200 ARB+CCB and 198 ARB+HCTZ). In FCs, the 
most commonly used ARB and CCB were valsartan (29.1%) and amlodipine (81.5%), 
respectively. The rates of BP goal achievement were higher among SPC vs. FC patients 
over time (p = 0.007): 30.5% vs. 28.3% at month 3 and 63.4% vs. 53.8% at month 
6. Cox regression conﬁrmed that SPC patients were more likely to achieve BP goal 
(HR = 1.22; p = 0.047). Similar trend was observed in the subgroup analyses compar-
ing SPC valsartan+amlodipine vs. FC ARB+CCB and SPC valsartan+HCTZ vs. FC 
ARB+HCTZ separately. CONCLUSIONS: Patients using valsartan-based SPC were 
more likely to achieve BP goal than those treated with ARB-based FC.
PCV16
AN ASSESSMENT OF OPTIMAL LIPID VALUE ATTAINMENT AND 
ASSOCIATED DYSLIPIDEMIA TREATMENT PATTERNS FROM 2005 TO 
2009 IN A COMMERCIALLY INSURED POPULATION
Tan H1, Yu J1, Bullano M2, Willey VJ3, Cziraky MJ1
1HealthCore, Inc., Wilmington, DE, USA, 2AstraZeneca, Wilmington, DE, USA, 3University of 
the Sciences in Philadelphia, Philadelphia, PA, USA
OBJECTIVES: Evidence-based guidelines for dyslipidemia therapy have provided 
deﬁnitive goals for low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) 
and suggested abnormal values for high-density lipoprotein cholesterol (HDL-C). The 
study objective was to determine lipid value attainment and dyslipidemia treatment 
rates. METHODS: Adult patients with two or more complete lipid panels from 
January 2005 through February 2009, regardless of dyslipidemia therapy, were identi-
ﬁed from the US nationally-representative HealthCore Integrated Research DatabaseTM 
(HIRD). Cardiovascular risk status was assigned based on National Cholesterol Edu-
cation Program (NCEP) criteria. Optimal lipid value (target) attainment was deﬁned 
using NCEP, American Heart Association, and American Diabetes Association crite-
ria. Target attainment for LDL-C, HDL-C and TG and lipid therapy treatment pat-
terns are described. RESULTS: A total of 227,903 patients were identiﬁed (mean 
follow-up = 1.9 years). At index lab, 21.1% of patients were at target for all three 
lipid fractions, 11.9% had no lipid fractions at target, 66.3% were at LDL-C target 
and 63.6% were not at target for either HDL-C or TG. Regardless of initial lipid 
fractions, only 28.7% of patients attained target over follow-up in all three lipid 
fractions. In patients with no lipid fractions at target at index, only 6.8% attained 
target for all lipid fractions and almost a third (31.9%) stayed at no lipid fractions at 
target; 44.4% of patients were receiving lipid-modifying therapy as of the last lipid 
lab (up from 33.0% at index), with twice as many on therapy attaining all targets 
versus no targets (66.6% vs. 29.0%). Statins were the most commonly used therapy 
(35.8%). CONCLUSIONS: Challenges to mixed dyslipidemia therapy still exist as 
evidenced by a minority of patients attaining optimal lipid values during the very 
recent timeframe of this study. These data may serve as valuable baseline benchmarks 
to evaluate the impact of new dyslipidemia guidelines and therapies.
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OBJECTIVES: Mortality of Stroke in China is highest in the world, having brought 
a heavy ﬁnancial burden to society. And the number of acute Ischemic Stroke 
accounted for 75% of the total cases. This study wants to evaluate the treatment 
program to ﬁnd a better cost effectiveness treatment to offer reference for patients and 
clinicians choosing the right treatment. METHODS: A total of 145 cases with acute 
Ischemic Stroke during a period of 2007 −2008 admitted in 21 hospitals in China 
were divided randomly into two groups. One group of 69 patients was treated by 
Butylphthalide sodium chloride injection and Aspirin, another group of 66 patients 
were treated by Ozagrel injection and Aspirin. Two kinds of therapy were evaluated 
by double-blind, double-dummy trial from patients’ perspective. Utility of patients 
was investigated with EQ-5D.Direct costs were collected from HIS and questionnaires, 
indirect costs were estimated based on the opportunity cost of the time for caring and 
curing. Probabilistic sensitivity analysis using nonparametric Bootstrapping was done. 
RESULTS: From the EQ-5D score we can learn that the improved values of 
Butylphthalide group score during 8–14 days and 15–90 days are higher than that of 
Ozagrel group, the average cost per QALY (Quality-Adjusted Life-year) of a patient 
for Butylphthalide group (RMB 225,753.4) was lower, with RMB 11,706.3, than 
Ozagrel group (RMB 237,459.7), and incremental costs were RMB 451,710.5[95%CI, 
RMB 218,689.55–1080, 313.05]. The acceptability curve generated from the ICUR 
can be seen the possibility of Ozagrel group having the cost –effectiveness advantage 
is zero if the willingness to pay per QALY is lower than RMB 192,000.CONCLU-
SIONS: Switching from the current programmed to Butylphthalide group is more 
cost-effective as compared to Ozagrel group.
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OBJECTIVES: To evaluate the effectiveness of a comprehensive lipoprotein proﬁle 
(VAP) test coupled with an aggressive treatment protocol when compared to a stan-
dard lipid proﬁle test in patients with ischemic heart disease (IHD) or congestive heart 
failure (CHF). METHODS: All WellMed health plan enrollees with a diagnosis of 
IHD or CHF who had continuous enrollment between July 1, 2006 and June 30, 2008 
were identiﬁed. The case group (n = 1767) having at least one VAP test during this 
period was compared with the control group (n = 289) having no lipid testing or 
traditional lipid testing only. Univariate statistics were analyzed to describe the groups, 
and bivariate statistical tests (t-test or chi-square) examined differences between the 
two cohorts. RESULTS: Use of a treatment protocol in conjunction with a VAP test 
resulted in a signiﬁcant decrease in LDL (−6.64 mg/dL, <0.001) as well as an increase 
in HDL (3.95 mg/dL, <0.001). Individuals in the control group saw a signiﬁcant 
decrease in LDL (−6.14 mg/dL, 0.002) but did not see a signiﬁcant change in HDL 
(−1.21 mg/dL, 0.076). Combination drug therapy was more commonly used for cases 
when compared to controls (average drug types 2.1 vs. 1.8, 0.0004); particularly, the 
use of niacin containing products was considerably higher in the case group when 
compared to the control group (36% vs. 14.4%, <0.0001). Mean total costs in year 
1 ($4,308 vs. $5,141, 0.1157) and year 2 ($4,853 vs. $7,413, 0.0255) were lower for 
cases. CONCLUSIONS: Greater utilization of combination therapy guided by the 
VAP test appears to better manage IHD and CHF patients to NHLBI ATP III HDL 
and LDL targets than controls receiving usual care guided by traditional lipid testing. 
Advanced lipid proﬁle tests appear to offer clinicians better information about their 
patients’ lipid abnormalities when compared to traditional testing.
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OBJECTIVES: To examine the comparative effectiveness of heparin 5000 units given 
subcutaneously twice a day or three times a day, enoxaparin 30 mg given subcutane-
ously twice a day, and enoxaparin 40 mg given subcutaneously daily for the preven-
tion of venous thromboembolism in burn patients. METHODS: A retrospective cohort 
study was conducted by using the hospital claims database. All adult patients were 
included if they were admitted to Shands hospital between January 1, 1998 and 
September 30, 2008, had primary diagnoses of burn, and received either subcutaneous 
heparin or enoxaparin for VTE prophylaxis. The primary outcome was a VTE event, 
which was identiﬁed by using a previously validated ICD-9 coding algorithm and 
further conﬁrmed by chart review for radiographic evidence. RESULTS: A total of 
1111 patients were included. Seven patients (0.63%) experienced VTE events: 5 
(0.83%) received heparin, 1 (0.92%) received enoxaparin 30 mg, and 1 (0.25%) 
received enoxaparin 40 mg. There were no incidences of heparin-induced thrombocy-
topenia identiﬁed in any group. CONCLUSIONS: The VTE incidence is low in burn 
patients receiving pharmacological prophylaxis. Both heparin and enoxaparin appear 
to be equally effective in preventing VTE complications in this patient population.
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OBJECTIVES: To quantitatively assess the potential beneﬁts and harms of using 
reduced-function CYP2C19 genotype information to guide the use of the antiplatelet 
